Articles

IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol

Department of Pediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany;
Department of Pediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany;
Department of Pediatric Hematology and Oncology, Hannover Medical School, Germany;
Department of Pediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany;
Department of Pediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany;
Division of Pediatric Oncology, University Children’s Hospital Zurich, Switzerland;
Department of Pediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany;
Department of Pediatric Hematology and Oncology, University Hospital Giessen and Marburg, Giessen, Germany;
Department of Pediatric Hematology and Oncology, University Hospital Giessen and Marburg, Giessen, Germany;
Department of Hematology, Oncology and Tumor Immunology, HELIOS-Clinic Berlin-Buch, Berlin, Germany;
Department of Hematology, Oncology and Tumor Immunology, HELIOS-Clinic Berlin-Buch, Berlin, Germany;
Department of Human Genetics, University of Heidelberg, Heidelberg, Germany
Department of Human Genetics, University of Heidelberg, Heidelberg, Germany
Department of Pediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany;
Department of Pediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany;
Department of Pediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany;
Vol. 98 No. 3 (2013): March, 2013 https://doi.org/10.3324/haematol.2011.056135